Toll-like receptors (TLR) are known to play a role in chronic pain, from animal models and limited research in humans, but their role in interstitial cystitis/bladder pain syndrome (IC/BPS) is unknown. Similarly, alterations of the hypothalamic-pituitary-adrenal axis have been reported in some pain conditions. Our objectives were to identify inflammatory processes that might distinguish individuals with IC/BPS from healthy controls (HC) and to examine their associations with IC/BPS symptoms. Female participants (58 IC/BPS patients and 28 HCs) completed pain and urinary symptom questionnaires and collected saliva for cortisol as part of the Multidisciplinary Approach to Pelvic Pain study. Inflammatory cytokines were assayed in plasma, and in TLR-2À and TLR-4-stimulated peripheral blood mononuclear cells. Controlling for BMI and negative affect, between-group differences were analyzed by general linear models, and relationships between symptoms and inflammatory variables were analyzed by regression. Compared to HCs, IC/BPS patients had higher levels of plasma interleukin-6 (P = .040), greater interleukin-1b responsive to TLR-2 stimulation (P = .040), and flatter diurnal cortisol slopes (P = .010), indicating inflammatory dysregulation. In IC/BPS patients, inflammation after TLR-4 stimulation was associated with multiple symptoms, including genitourinary pain (P = .010), sexual pain (P = .002), and marginally with urinary symptoms (P = .068). Genitourinary pain severity (P = .008), frequency (P = .001), and pain with intercourse (P = .002) were strongly associated with TLR-4 inflammatory response. TLR-4 appears to play a central role in painful symptoms of IC/BPS patients, which may be linked to poor endogenous inflammatory control. These findings may help to identify new mechanisms in IC/BPS and lead to new therapeutic approaches. Ó
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Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic condition associated with urinary symptoms including urgency, frequency, nocturia, and pelvic pain. Berry and co-authors report the prevalence of IC/BPS at between 3 and 8 million women in the United States [3] . Few patients achieve long-term remission of symptoms despite a range of treatments [1, 31] . A substantial body of research has explored bladder pathology and other peripheral tissue abnormalities; however, a large number of IC/BPS patients lack any discernible end organ inflammation, and do not respond to treatment of peripheral tissues (eg, hydrodistention of bladder) [29] . This suggests that investigation of more systemic factors (eg, inflammation, inflammatory control) may yield important insights. IC/BPS patients have a high prevalence of comorbid Functional Somatic Syndromes (FSSs), such as irritable bowel syndrome (IBS) and fibromyalgia (FM), which are also characterized by chronic pain in the absence of clearly identifiable peripheral pathology [6, 26] . This suggests that altered central pain processing (eg, hyperalgesia, allodynia) 
